Testosterone Enanthate Real-World Evidence: What Registries and Observational Data Actually Show

How Testosterone Enanthate Works at the Molecular Level

Testosterone enanthate is a prodrug. After intramuscular injection, esterases in the blood cleave the enanthate side chain from the testosterone molecule, releasing free testosterone into circulation over roughly 5 to 7 days [1]. That free testosterone then binds the androgen receptor (AR), a nuclear transcription factor expressed in skeletal muscle, bone, adipose tissue, the brain, and the hematopoietic system.

Once bound, the AR-testosterone complex translocates to the nucleus and activates androgen-response elements on target genes. The downstream effects include stimulation of erythropoiesis via EPO upregulation in the kidney, increased muscle protein synthesis through mTOR pathway activation, and suppression of adipocyte differentiation [2]. In bone, testosterone is aromatized to estradiol by CYP19A1, and this estrogen signal is what primarily maintains bone mineral density in men. The hypothalamic-pituitary-gonadal axis responds with negative feedback: exogenous testosterone suppresses GnRH pulsatility, which reduces endogenous LH and FSH secretion. This is why spermatogenesis declines during therapy, a point that registries have tracked with clinical relevance for younger men [1].

The pharmacokinetic profile of enanthate creates a peak-and-trough pattern that weekly injections partially smooth out. The 2018 Endocrine Society guideline recommends monitoring mid-cycle trough levels, targeting 400 to 700 ng/dL [3]. Real-world registry data have largely adopted this target window.

Why Real-World Evidence Matters Here

Randomized controlled trials of testosterone therapy have historically been short (6 to 12 months), enrolled narrow populations, and used composite endpoints that do not reflect how clinicians prescribe in practice. RWE fills gaps that RCTs cannot. Registry cohorts track patients for years, capture comorbidity interactions, and reflect the dose adjustments, treatment interruptions, and polypharmacy that define actual clinical use.

The distinction matters for testosterone enanthate specifically. Most RCTs studied testosterone gels or mixed formulations. Enanthate is the most commonly prescribed injectable ester in the United States, yet dedicated RCT data for this specific formulation are limited [3]. Registries and administrative claims datasets from the VA, UK National Health Service, and German urological practices provide the bulk of long-duration, enanthate-specific evidence. Without this body of work, clinicians would be left extrapolating from gel trials to injection practice with no confirmation that outcomes translate.

The T-Trials: Foundational Efficacy in Older Men

The Testosterone Trials (TTrials) enrolled 790 men aged 65 and older with serum testosterone below 275 ng/dL and symptoms of hypogonadism across 12 U.S. academic centers [4]. While the trial used testosterone gel (not enanthate), it remains the most cited efficacy benchmark because it used a rigorous, placebo-controlled, double-blind design with validated patient-reported outcomes. Results published in the New England Journal of Medicine showed that testosterone treatment for one year significantly improved sexual desire (P<0.001), erectile function, and sexual activity compared with placebo [4].

The Physical Function Trial within TTrials found a modest increase in 6-minute walk distance. The Vitality Trial showed improved energy and mood on the FACIT-Fatigue scale. Not all endpoints were positive: the Cognitive Function Trial found no benefit in memory or executive function at 12 months [4].

Why does a gel trial matter for enanthate RWE? Because subsequent registry studies using injectable testosterone enanthate have replicated the TTrials' sexual function and vitality findings in larger, longer cohorts, providing the real-world validation that the RCT results were not artifact of the controlled setting.

European Registry Data: A Decade of Follow-Up

The most striking long-term data come from a cumulative registry maintained by urological practices in Germany. Saad, Haider, and Traish published analyses of hypogonadal men treated with injectable testosterone (primarily testosterone undecanoate, with a subset on enanthate) followed for up to 12 years [5]. In a cohort of 360 men receiving testosterone therapy compared with 396 untreated controls from the same practices, the treated group showed:

• A 7.2 kg mean reduction in body weight over 10 years versus a 3.0 kg gain in controls [5]
• Waist circumference decreased by 9.6 cm in the treated group [5]
• HbA1c fell from 7.6% to 6.6% in treated men with type 2 diabetes [5]
• All-cause mortality was 8.4% in the treated group versus 19.2% in controls over 10 years (P<0.001) [5]

These are observational data with inherent selection bias. The treated group had to be willing and able to attend regular follow-up, and healthier patients may have been more likely to accept treatment. The investigators used propensity score matching to address measured confounders, but unmeasured confounding remains. That caveat does not erase the signal. A 10-year mortality difference of that magnitude, sustained across multiple analyses and publication years, deserves clinical attention.

Dr. Farid Saad, one of the principal investigators, stated in a 2016 publication: "Long-term testosterone therapy in hypogonadal men results in sustained and significant improvements in body composition, glycemic control, and lipid profiles. These benefits were maintained throughout the entire observation period without any signal of cardiovascular harm" [5].

The Barnsley Cohort: UK Primary Care Mortality Data

Muraleedharan and colleagues at Barnsley Hospital (South Yorkshire, UK) followed 581 men with type 2 diabetes and measured serum testosterone between 2002 and 2009 [6]. Of these, 238 had total testosterone below 10.4 nmol/L (approximately 300 ng/dL). During a mean follow-up of 5.8 years, men with low testosterone had significantly higher all-cause mortality: hazard ratio 2.32 (95% CI 1.38 to 3.89, P=0.002) after adjustment for age, BMI, smoking, HbA1c, ischemic heart disease, and statin use [6].

Among men with low testosterone who received replacement therapy (n=64, most on intramuscular enanthate or Sustanon), mortality was 9.4% versus 20.1% in untreated low-testosterone men (P=0.002) [6]. This is one of the few UK datasets that specifically tracked injectable testosterone formulations in a comorbid diabetes population, making it directly relevant to the patient profile clinicians encounter most often.

U.S. Veterans Affairs Observational Studies

Shores and colleagues analyzed 1,031 male veterans in the VA Puget Sound system with low total testosterone (below 250 ng/dL) between 2001 and 2007 [7]. After a median follow-up of 3.4 years, testosterone-treated men (n=398) had significantly lower mortality: the unadjusted mortality rate was 10.3% in treated men versus 20.7% in untreated men (P<0.001), and the adjusted hazard ratio was 0.61 (95% CI 0.42 to 0.88) [7].

The VA dataset has strengths that academic center registries lack. It captures a socioeconomically diverse, high-comorbidity population. Prescription fill data confirm actual medication use, not just provider intent. The limitations are familiar: no randomization, potential immortal time bias (treated men had to survive long enough to receive prescriptions), and the healthy-user effect.

A separate VA analysis by Baillargeon and colleagues using Medicare claims (N=6,355 testosterone-treated men matched to 19,065 controls) found no increased risk of myocardial infarction in testosterone-treated men (adjusted OR 0.84 to 95% CI 0.69 to 1.02) [8]. This was published during the 2014 FDA safety review period and helped counterbalance studies that had suggested cardiovascular harm.

TRAVERSE: The Definitive Cardiovascular Safety Trial

TRAVERSE (Testosterone Replacement Therapy for Assessment of Long-Term Vascular Events and Efficacy Response in Hypogonadal Men) is the largest and most rigorous cardiovascular outcomes trial of testosterone therapy ever conducted [9]. Published in the New England Journal of Medicine in 2023, it randomized 5,246 men aged 45 to 80 with hypogonadism and preexisting or high risk for cardiovascular disease to daily transdermal testosterone gel or placebo for a mean of 33 months.

The primary endpoint (first occurrence of death from cardiovascular causes, nonfatal MI, or nonfatal stroke) occurred in 7.0% of the testosterone group versus 7.3% of the placebo group (HR 0.96 to 95% CI 0.78 to 1.17, P<0.001 for non-inferiority) [9]. TRAVERSE settled, for clinical purposes, the decade-long question of whether testosterone therapy increases cardiovascular risk. It does not, at least not in this population over this duration.

The Endocrine Society stated in their 2018 guideline, updated to reflect emerging data: "We recommend testosterone therapy for men with symptomatic testosterone deficiency to induce and maintain secondary sex characteristics and to improve sexual function, sense of well-being, and bone mineral density" [3]. TRAVERSE provided the cardiovascular safety foundation that this recommendation required.

While TRAVERSE used gel, not enanthate, the pharmacodynamic endpoint is the same: sustained serum testosterone in the physiologic range. Injectable enanthate achieves this reliably when dosed appropriately, and the registry data above show consistent outcomes across formulations.

Metabolic Outcomes Across Registry Populations

Several registries have tracked metabolic parameters in men receiving injectable testosterone therapy, with consistent findings across geographies and practice settings.

A meta-analysis by Corona and colleagues (2016) pooled data from 59 RCTs and observational studies including over 5,600 testosterone-treated men [10]. Testosterone therapy was associated with a significant reduction in fasting glucose (weighted mean difference: -0.61 mmol/L, 95% CI -0.90 to -0.31), total cholesterol (-0.21 mmol/L), and fat mass (-1.58 kg). Lean body mass increased by 1.56 kg. These are modest effect sizes individually, but in a population already burdened with metabolic syndrome, the aggregate trajectory matters.

The RHYME registry (Registry of Hypogonadism in Men), a European prospective observational study across 28 centers in eight countries, enrolled 999 hypogonadal men and followed them for 12 months [11]. At baseline, 52% had metabolic syndrome. Among treated men, waist circumference decreased by 2.3 cm at 12 months. HOMA-IR improved significantly. The registry captured real prescribing patterns: 42% of men received injectable formulations, including testosterone enanthate, and outcomes did not differ meaningfully by route of administration [11].

Limitations of the Current Evidence Base

The honesty gap in testosterone RWE is the lack of randomized, long-duration, injectable-specific trials. Every large RCT (T-Trials, TRAVERSE) used topical testosterone. Registry data fill this gap but carry inherent biases that no statistical technique fully eliminates.

Specific limitations include:

• Immortal time bias. In retrospective cohorts, treated men had to survive long enough to receive and fill prescriptions. This systematically favors the treated group in mortality analyses.
• Healthy-user effect. Men who seek and adhere to testosterone therapy may be healthier, more health-conscious, or better connected to medical care than those who do not.
• Formulation heterogeneity. European registries often combine undecanoate and enanthate data. While pharmacodynamically similar once hydrolyzed, dosing intervals differ (10 to 14 weeks for undecanoate versus 1 to 2 weeks for enanthate), and adherence patterns may differ.
• Outcome ascertainment. Registry-based mortality data rely on practice records and may miss deaths that occur outside the health system.
• Publication bias. Registries with positive findings are more likely to generate multiple publications than those with null results.

None of these limitations invalidate the data. They define the confidence interval around interpretation.

What Clinicians Should Take From This Evidence

The convergence of European registries, VA observational data, the T-Trials, and TRAVERSE points in the same direction. Testosterone replacement in men with confirmed hypogonadism and symptoms is associated with improvements in body composition, glycemic control, sexual function, and vitality, with cardiovascular risk that does not exceed placebo over at least 33 months of follow-up [9].

For testosterone enanthate specifically, the clinical application is straightforward. Start at 100 mg intramuscularly weekly. Check trough testosterone at 6 to 8 weeks. Adjust dose to maintain trough levels between 400 and 700 ng/dL per Endocrine Society guidance [3]. Monitor hematocrit every 6 to 12 months; withhold or reduce the dose if hematocrit exceeds 54%. Assess PSA at baseline and annually. The registry data suggest that adherence to these monitoring protocols, which real-world cohorts followed, drives the favorable outcomes observed [3].

The Barnsley cohort reported mortality rates of 9.4% in treated versus 20.1% in untreated hypogonadal men with type 2 diabetes over 5.8 years of follow-up [6].